公开(公告)号：US20230047314A1

公开(公告)日：2023-02-16

申请号：US17952300

申请日：2022-09-25

Applicant: INTELGENX CORP.

Inventor： Nadine PAIEMENT ,  Rodolphe OBEID ,  Justin CONWAY ,  Billal TIR

IPC: A61K9/00 ,  A61K47/38 ,  A61K31/4985

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm

公开(公告)号：US20220395452A1

公开(公告)日：2022-12-15

申请号：US17732456

申请日：2022-04-28

Applicant: INTELGENX CORP.

Inventor： Nadine PAIEMENT ,  Horst G. ZERBE ,  Justin W. CONWAY ,  Rodolphe OBEID ,  Ludwig AIGNER ,  Johanna MICHAEL

IPC: A61K9/00 ,  A61K31/47 ,  A61K47/36 ,  A61K47/26 ,  A61K47/18 ,  A61K47/38 ,  A61K47/02 ,  A61K47/12 ,  A61K47/10

Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

公开(公告)号：US20220362164A1

公开(公告)日：2022-11-17

申请号：US17729442

申请日：2022-04-26

Applicant: INTELGENX CORP.

Inventor： Nadine PAIEMENT ,  Horst G. ZERBE ,  Justin W. CONWAY ,  Rodolphe OBEID

IPC: A61K9/70 ,  A61K31/47 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K9/00

Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

公开(公告)号：US20210022991A1

公开(公告)日：2021-01-28

申请号：US17063644

申请日：2020-10-05

Applicant: INTELGENX CORP.

Inventor： Nadine PAIEMENT ,  Rodolphe OBEID ,  Justin CONWAY ,  Billal TIR

IPC: A61K9/00 ,  A61K47/38 ,  A61K31/4985

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm

公开(公告)号：US20250120908A1

公开(公告)日：2025-04-17

申请号：US18928201

申请日：2024-10-28

Applicant: INTELGENX CORP.

Inventor： Nadine PAIEMENT ,  Rodolphe OBEID ,  Justin CONWAY ,  Billal TIR

IPC: A61K9/00 ,  A61K31/4985 ,  A61K47/38

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm

公开(公告)号：US20230201130A1

公开(公告)日：2023-06-29

申请号：US18110879

申请日：2023-02-16

Applicant: INTELGENX CORP.

Inventor： Carolin MADWAR ,  Nadine PAIEMENT ,  Rodolphe OBEID ,  Justin CONWAY ,  Erick GONZALEZ-LABRADA

IPC: A61K9/70 ,  A61K31/352 ,  A61K31/47 ,  A61K9/00

CPC classification number: A61K9/7007 ,  A61K31/352 ,  A61K31/47 ,  A61K9/006

Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.

公开(公告)号：US20210393611A1

公开(公告)日：2021-12-23

申请号：US17291582

申请日：2019-11-04

Applicant: INTELGENX CORP.

Inventor： Carolin MADWAR ,  Nadine PAIEMENT ,  Rodolphe OBEID ,  Justin W. CONWAY ,  Erick GONZALEZ-LABRADA

IPC: A61K31/47 ,  A61K9/00 ,  A61K9/107 ,  A61K31/352 ,  A61K47/44

Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.